

Our vision

Disrupting neuroscience
Give patients hope

We are convinced that NETRI’s expertise can bring hope to patients with neurological diseases by inventing innovative and high-end technologies and services, that are not yet available on the market.
New and disruptive approaches can be invented, through :



the understanding



the modeling



the improvement of existing treatment, for the benefit of all patients

Our mission

NETRI can change the way neurological diseases are treated, by acting and thinking differently.

We are committed to

Increasing discoveries on the brain and neurology
Contributing to the invention of new, personalized, and relevant disruptive treatment approaches

Speeding up the market entry of these approaches
Alleviating the suffering of patients and their relatives
Ethic position on animal testing

Our strategic priorities

We believe neurological disorders need an urgent response and are therefore our top strategic investment priorities

4 pathologies

NETRI focuses on 4 major global
diseases and epidemics

Alzheimer’s disease,
Parkisnon’s disease,
Huntington‘s disease,
Pain

4 Models

Organ-on-chip devices to model neurological disorders

14 devices

Exploration of a neurological compound : structural and functional mode of action

Axonal growth,
Functional recording,
Growth kinetics,
Synaptic toxicity,
Vesicular transport,

Our R&D programs

We are comited to continuously investing in research programs to

Develop new in vitro models and demonstrate their physiological relevance: neurofluidic models of Alzheimer’s and Parkison’s diseases and their injuries, degeneration of Lewy body, Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Lobar Degeneration (FLD), gut-brain axis and innervated epidermis
Develop Standard Operating Protocols (SOP) for human induced pluripotent stem cells (iPScs) and patient-derived iPSCs differentiated neurons in our neurofluidic devices
Develop the first in vitro differential diagnostic medical device for neurological troubles, in collaboration with Lyon’s Hospital
Seeking partners for joint development with pharmaceutical industrials